These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22334798)

  • 21. Inhibition of water absorption in human proximal tubular epithelial cells in response to Shiga toxin-2.
    Silberstein C; Pistone Creydt V; Gerhardt E; Núñez P; Ibarra C
    Pediatr Nephrol; 2008 Nov; 23(11):1981-90. PubMed ID: 18607643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary concentrating defect in rats given Shiga toxin: elevation in urinary AQP2 level associated with polyuria.
    Sugatani J; Komiyama N; Mochizuki T; Hoshino M; Miyamoto D; Igarashi T; Hoshi S; Miwa M
    Life Sci; 2002 May; 71(2):171-89. PubMed ID: 12031687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progression of microalbuminuria in SHR is associated with lower expression of critical components of the apical endocytic machinery in the renal proximal tubule.
    Inoue BH; Arruda-Junior DF; Campos LC; Barreto AL; Rodrigues MV; Krieger JE; Girardi AC
    Am J Physiol Renal Physiol; 2013 Jul; 305(2):F216-26. PubMed ID: 23637208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome.
    Ylinen E; Salmenlinna S; Halkilahti J; Jahnukainen T; Korhonen L; Virkkala T; Rimhanen-Finne R; Nuutinen M; Kataja J; Arikoski P; Linkosalo L; Bai X; Matussek A; Jalanko H; Saxén H
    Pediatr Nephrol; 2020 Sep; 35(9):1749-1759. PubMed ID: 32323005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of an experimental hemolytic uremic syndrome in rats.
    Zotta E; Lago N; Ochoa F; Repetto HA; Ibarra C
    Pediatr Nephrol; 2008 Apr; 23(4):559-67. PubMed ID: 18253762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
    Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI
    Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A glucosylceramide synthase inhibitor protects rats against the cytotoxic effects of shiga toxin 2.
    Silberstein C; Lucero MS; Zotta E; Copeland DP; Lingyun L; Repetto HA; Ibarra C
    Pediatr Res; 2011 May; 69(5 Pt 1):390-4. PubMed ID: 21270676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ouabain Protects Human Renal Cells against the Cytotoxic Effects of Shiga Toxin Type 2 and Subtilase Cytotoxin.
    Amaral MM; Girard MC; Álvarez RS; Paton AW; Paton JC; Repetto HA; Sacerdoti F; Ibarra CA
    Toxins (Basel); 2017 Jul; 9(7):. PubMed ID: 28718802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody response to Shiga toxins in Argentinean children with enteropathic hemolytic uremic syndrome at acute and long-term follow-up periods.
    Fernández-Brando RJ; Bentancor LV; Mejías MP; Ramos MV; Exeni A; Exeni C; Laso Mdel C; Exeni R; Isturiz MA; Palermo MS
    PLoS One; 2011 Apr; 6(4):e19136. PubMed ID: 21559455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytotoxic effect of Shiga toxin-2 holotoxin and its B subunit on human renal tubular epithelial cells.
    Creydt VP; Silberstein C; Zotta E; Ibarra C
    Microbes Infect; 2006 Feb; 8(2):410-9. PubMed ID: 16242986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diet-induced obesity precipitates kidney dysfunction and alters inflammatory mediators in mice treated with Shiga Toxin 2.
    Harrison LM; Gaines DW; Babu US; Balan KV; Reimschuessel R; Do AB; Pereira MR; Bigley EC; Ferguson M; Mehta A; Williams KM
    Microb Pathog; 2018 Oct; 123():250-258. PubMed ID: 30016681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008.
    Jenssen GR; Vold L; Hovland E; Bangstad HJ; Nygård K; Bjerre A
    BMC Infect Dis; 2016 Jun; 16():285. PubMed ID: 27297224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hemolytic uremic syndrome in children of Mendoza, Argentina: association with Shiga toxin-producing Escherichia coli infection].
    Rivas M; Balbi L; Miliwebsky ES; García B; Tous MI; Leardini NA; Prieto MA; Chillemi GM; de Principi ME
    Medicina (B Aires); 1998; 58(1):1-7. PubMed ID: 9674201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcome of diarrhea-associated hemolytic uremic syndrome is poorly related to markers of kidney injury at 1-year follow-up in a population-based cohort.
    Monet-Didailler C; Godron-Dubrasquet A; Madden I; Delmas Y; Llanas B; Harambat J
    Pediatr Nephrol; 2019 Apr; 34(4):657-662. PubMed ID: 30368614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model.
    Palermo MS; Alves Rosa MF; Van Rooijen N; Isturiz MA
    Clin Exp Immunol; 1999 Jun; 116(3):462-7. PubMed ID: 10361235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum Shiga toxin 2 values in patients during acute phase of diarrhoea-associated haemolytic uraemic syndrome.
    He X; Quiñones B; Loo MT; Loos S; Scavia G; Brigotti M; Levtchenko E; Monnens L
    Acta Paediatr; 2015 Dec; 104(12):e564-8. PubMed ID: 26361237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against Hemolytic Uremic Syndrome (HUS).
    Mejías MP; Hiriart Y; Lauché C; Fernández-Brando RJ; Pardo R; Bruballa A; Ramos MV; Goldbaum FA; Palermo MS; Zylberman V
    Sci Rep; 2016 Apr; 6():24913. PubMed ID: 27118524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is Shigatoxin 1 protective for the development of Shigatoxin 2-related hemolytic uremic syndrome in children? Data from the ItalKid-HUS Network.
    Ardissino G; Possenti I; Vignati C; Daprai L; Capone V; Brigotti M; Luini MV; Consonni D; Montini G
    Pediatr Nephrol; 2020 Oct; 35(10):1997-2001. PubMed ID: 32734345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rab7b participation on the TLR4 (Toll-like receptor) endocytic pathway in Shiga toxin-associated Hemolytic Uremic Syndrome (HUS).
    Lafalla Manzano AF; Gil Lorenzo AF; Bocanegra V; Costantino VV; Cacciamani V; Benardon ME; Vallés PG
    Cytokine; 2019 Sep; 121():154732. PubMed ID: 31153054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mouse model for hemolytic uremic syndrome induced by outer membrane vesicles of Escherichia coli O157:H7.
    Kim SH; Lee YH; Lee SH; Lee SR; Huh JW; Kim SU; Chang KT
    FEMS Immunol Med Microbiol; 2011 Dec; 63(3):427-34. PubMed ID: 22029600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.